Advanced Capabilities in 505(b)(2) Filings, Complex Generics, Specialty Pharmaceuticals & Novel Delivery Systems

Taj Pharma’s formulation development (FD) division is a core strategic pillar of the organization, designed to translate scientific innovation into high-quality, globally compliant pharmaceutical, nutraceutical, and medical food products. With a multidisciplinary team of formulation scientists, regulatory experts, analytical chemists, and technology specialists, Taj Pharma has built an advanced platform to develop complex, high-value, and competitive formulations for global markets.

The department operates under WHO-GMP, PIC/S, and stringent international regulatory standards, enabling seamless expansion into both mature (US/EU/UK/Australia) and semi-regulated markets (Asia, MENA, Africa, CIS, LATAM).

1. Regulatory Expertise & Strategic Filing Capabilities

1.1 Expertise in 505(b)(2) Regulatory Filings (USFDA Pathway)

Taj Pharma has a specialized focus on 505(b)(2) NDAs, which allow the company to leverage existing scientific literature while incorporating modifications that improve therapeutic outcomes.
Key expertise areas include:

  • Reformulation of existing APIs for improved bioavailability (enhanced solubility, permeability).
  • Novel fixed-dose combinations (FDCs) using already approved ingredients.
  • New routes of administration (oral → injectable, oral → transdermal).
  • Modified-release (MR/ER) platforms to reduce dosing frequency or enhance compliance.
  • Lower-dose and high-strength variants backed by pharmacokinetic bridging data.
  • Complex generics developed into differentiation-based 505(b)(2) candidates (e.g., abuse-deterrent opioids, long-acting injectables).

The company is proficient in integrating BA/BE studies, CMC modules, stability data, and comparability protocols into 505(b)(2) submissions.

1.2 Complex Generics Development

Taj Pharma’s formulation team specializes in difficult-to-develop generic products that require advanced process engineering and specialized analytical characterization.

Areas of strength include:

  • Low-solubility BCS Class II & IV drugs (solid dispersion, micronization).
  • Products requiring particle-size engineering and controlled crystallinity.
  • Hormonal, cytotoxic, and immunosuppressive products.
  • Liposomal and nanoparticulate formulations.
  • Complex ophthalmics (sterile emulsions, suspensions, gels).
  • Inhalation and nasal drug delivery (solution & suspension aerosols).

The company’s complex generic programmes focus on:

  • Q1/Q2 sameness compliance
  • Critical Quality Attribute (CQA) mapping
  • ANDA filing strategy with robust in vitro/in vivo correlations

1.3 FTF (First-to-File) & Patent-Challenge Expertise

Taj Pharma maintains a specialized IP and formulation innovation group responsible for Para IV filings and FTF opportunities.

Capabilities include:

  • Patent landscaping, claim interpretation & infringement assessment
  • Designing non-infringing but therapeutically equivalent formulations
  • Alternative salt forms, polymorph screening, particle engineering
  • Novel excipient strategies to bypass formulation patents
  • Highly accelerated development to secure FTF exclusivity windows

This vertical enables Taj Pharma to compete in high-value markets with limited competition and exclusivity potential.

1.4 Nutraceuticals, Medical Foods & Dietary Supplements

Taj Pharma develops advanced nutraceutical and wellness products based on evidence-based formulations, supported by:

  • Clinical research data
  • GRAS-listed excipients
  • High-bioavailability formats (liposomal, micro-encapsulated, sustained release)

Product categories include:

  • Immunity, anti-inflammatory, cardiac wellness
  • Joint and bone health
  • Metabolic & diabetes support
  • Pediatric nutrition
  • Advanced probiotics and synbiotics
  • Specialized medical foods for oncology, renal health, and diabetes care

2. Dosage Forms Developed by Taj Pharma

Taj Pharma’s formulation portfolio spans almost all major dosage form categories, developed with scale-up capability for global exports.

2.1 Oral Solid Dosage Forms

Tablets

  • Immediate Release (IR)
  • Extended Release (ER/MR)
  • Orally Disintegrating Tablets (ODTs)
  • Chewable tablets
  • Effervescent tablets
  • Bilayer tablets
  • High-potency & low-dose precision tablets

Capsules

  • Hard gelatin or HPMC capsules
  • Modified-release pellets inside capsules
  • Powder-filled capsules
  • Liquid-filled capsules
  • Multi-particulate systems

Pellets

  • Sustained release pellets
  • Enteric-coated pellets
  • Taste-masked pellets
  • Combination multilayer pellets

2.2 Oral Liquid Formulations

  • Syrups
  • Suspensions
  • Oral drops
  • Solutions with solubility-enhanced systems
  • Pediatric-friendly & sugar-free formulations

2.3 Injectable/Parenteral Dosage Forms

Taj Pharma develops a broad category of sterile injectables, including:

  • Liquid injectables (aqueous/non-aqueous)
  • Lyophilized powders
  • Ready-to-use (RTU) and ready-to-administer (RTA) formulations
  • Pre-filled syringes (PFS)
  • Complex injectables, such as
    • Liposomal formulations
    • Depot injections
    • Emulsion-based injectables
    • Reconstitutable powders

The company also manages sterile facility validations, media fills, and aseptic processing excellence aligned with USFDA/PIC/S expectations.

2.4 Ophthalmic & ENT Formulations

Capabilities include:

  • Sterile ophthalmic solutions
  • Suspensions with precise particle size control
  • Emulsions
  • Gel-based ophthalmics
  • Multidose preservative-free systems (advanced closures)

3. Core Technologies & Advanced Manufacturing Capabilities

Taj Pharma’s R&D utilizes state-of-the-art technologies to develop stable, cost-effective, and globally compliant formulations.

3.1 High-Shear Granulation

  • Ideal for moisture-sensitive and compressibility-challenged APIs
  • Controls particle size distribution and blend uniformity
  • Used extensively for immediate-release and some MR formulations

3.2 Fluid-Bed Granulation

  • Enables spray granulation, top-spray, and bottom-spray processes
  • Provides superior flow properties and compressibility
  • Suitable for solubility enhancement and pellet coating

3.3 Roller Compaction (Dry Granulation)

Used for APIs sensitive to heat or moisture. Benefits include:

  • Precise powder densification
  • Excellent flowability without solvent exposure
  • Ideal for high-potency and poorly compressible APIs

3.4 Wurster Coating (Bottom-Spray Coating)

Taj Pharma uses Wurster coating for:

  • Sustained-release pellets
  • Enteric-coated multiparticulates
  • Taste-masking layers
  • Combination pellet-filled capsule products

This ensures uniform deposition, optimized release profiles, and stability.

3.5 Encapsulation Technologies

Capabilities include:

  • Multiple pellet filling
  • Powder and granule encapsulation
  • Liquid and semi-solid fill capsules
  • Band sealing for leak-proof stability

Applications include complex FDCs and modified-release systems.

3.6 Micronization & Particle-Size Engineering

Using jet-mill technology to achieve:

  • Enhanced dissolution rate
  • Improved bioavailability
  • Narrow PSD (particle-size distribution) control
  • Critical for BCS Class II & IV molecules

3.7 Injectable Formulation Technologies

Sterile formulation technologies include:

  • Aseptic compounding
  • Terminal sterilization
  • Lyophilization cycle design
  • Particle-free manufacturing
  • Oil-based injectable preparation
  • Solubility enhancement for poorly soluble injectables
  • Complex sterile suspensions

4. Quality-by-Design (QbD) & Analytical Excellence

Taj Pharma adopts QbD principles across all formulation development stages:

  • Risk assessment (FMEA, Ishikawa)
  • CQA and CPP identification
  • Design of Experiments (DOE)
  • Control strategy development
  • Robust scale-up for commercial manufacturing

The analytical team supports development with:

  • Stability-indicating method development
  • Forced degradation studies
  • Impurity profiling
  • Dissolution method optimization
  • IVIVC where applicable

5. Scale-Up & Technology Transfer

Taj Pharma has a strong system for pilot-scale manufacturing followed by smooth tech-transfer to commercial units:

  • GMP-compliant pilot plants
  • Tech-transfer documentation (TTD) aligned with global standards
  • Process validation & PPQ batches
  • Commercial-scale optimization

This ensures minimal downtime and successful product launch in any global market.

6. Competitive Advantages of Taj Pharma’s FD Department

  • End-to-end development from concept → dossier → commercialization.
  • Ability to handle cytotoxics, hormones, immunosuppressives, and high-potency APIs.
  • Strong regulatory intelligence for USFDA, EMA, MHRA, TGA, HC, WHO, PIC/S markets.
  • Robust stability data aligned with ICH guidelines.
  • Flexible development for partnered projects, CDMO, and co-development programs.
  • Strong pipeline of FTF, Para IV, and complex generics.

Taj Pharma’s formulation development division is built on strong scientific capabilities, state-of-the-art technologies, and regulatory expertise. Its proven experience with 505(b)(2) filings, complex generics, sterile products, nutraceuticals, ophthalmics, and high-value specialty dosage forms positions the company as one of the most versatile and innovation-driven pharmaceutical manufacturers from India.

Whether for global ANDA/NDA filings, regulated market partnerships, or large-scale international supply programmes, Taj Pharma delivers scientifically robust, regulatory-ready, and commercially competitive formulations.